Onboarding : och dess förekomst inom åländska organisationer

I detta examensarbete skriver jag om ämnet Onboarding av nyanställda, ett brett ämne som under senare år fått större betydelse inom HR-arbete i organisationer. Syftet med examensarbetet är att ge läsaren en bred bild av ämnet och vilka aspekter temat berör samt med hjälp av examensarbetets kvantitativa undersökning ta reda på om det implementerats inom åländska organisationer. Teorier och aspekter som tas upp i arbetet är bl.a. nyttan med onboarding, organisatorisk socialisering, orientering och lärande, gruppdynamik, värdegrunder etc. Dessa teorier ligger sedan till grund för frågorna som arbetets kvantitativa studie tar upp. Resultatet från examensarbetets kvantitativa studie visar att de åländska organisationer som deltog har etablerat onboarding i sitt HR-arbete inom organisationen som korrelerar med arbetets teorier kring ämnet onboarding av nyanställda

Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway

Background: In 2015, Norway implemented cancer patient pathways to reduce waiting times for treatment. The aims of this paper were to describe patterns in waiting time and their association with patient characteristics for colorectal, lung, breast and prostate cancers. Methods: National, population-based data from 2007 to 2016 were used. A multivariable quantile regression examined the association between treatment period, age, stage, sex, place of residence, and median waiting times. Results: Reduction in median waiting times for radiotherapy among colorectal, lung and prostate cancer patients ranged from 14 to 50 days. Median waiting time for surgery remained approximately 21 days for both colorectal and breast cancers, while it decreased by 7 and 36 days for lung and prostate cancers, respectively. The proportion of lung and prostate cancer patients with metastatic disease at the time of diagnosis decreased, while the proportion of colorectal patients with localised disease and patients with stage I breast cancer increased (p < 0.001). After adjusting for case-mix, a patient’s place of residence was significantly associated with waiting time for treatment (p < 0.001), however, differences in waiting time to treatment decreased over the study period. Conclusions: Between 2007 and 2016, Norway experienced improved stage distributions and consistently decreasing waiting times for treatment. While these improvements occurred gradually, no significant change was observed from the time of cancer patient pathway implementation

Explaining Movements in the Norwegian Exchange Rate

This issue of Norges Bank's Occasional Papers contains a number of signed articles written by employees of Norges Bank, which use different approaches and methods to look at factors that may help us to understand movements in the exchange rate. The analyses were carried out in Norges Bank in 2002 and preliminary results were presented at a seminar for the Ministry of Finance and Statistics Norway on 7 February 2003

Hvilke faktorer kan forklare utviklingen i valutakursen?

Denne utgaven av Norges Banks skriftserie inneholder en rekke signerte artikler skrevet av medarbeidere i Norges Bank som ved hjelp av ulike innfallsvinkler og metoder drøfter forhold som kan hjelpe oss med å forstå utviklingen i valutakursen. Analysene er gjennomført i Norges Bank i løpet av 2002, og ble presentert på et seminar for Finansdepartementet og Statistisk sentralbyrå 7. februar 2003

Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer

Antiangiogenic drugs are potentially a useful supplement to neoadjuvant chemotherapy for a subgroup of patients with human epidermal growth factor receptor 2 (HER2) negative breast cancer, but reliable biomarkers for improved response are lacking. Here, we report on a randomized phase II clinical trial to study the added effect of bevacizumab in neoadjuvant chemotherapy with FEC100 (5‐fluorouracil, epirubicin and cyclophosphamide) and taxanes (n = 132 patients). Gene expression from the tumors was obtained before neoadjuvant treatment, and treatment response was evaluated by residual cancer burden (RCB) at time of surgery. Bevacizumab increased the proportion of complete responders (RCB class 0) from 5% to 20% among patients with estrogen receptor (ER) positive tumors (P = .02). Treatment with bevacizumab was associated with improved 8‐year disease‐free survival (P = .03) among the good responders (RCB class 0 or I). Patients treated with paclitaxel (n = 45) responded better than those treated with docetaxel (n = 21; P = .03). Improved treatment response was associated with higher proliferation rate and an immune phenotype characterized by high presence of classically activated M1 macrophages, activated NK cells and memory activated CD4 T cells. Treatment with bevacizumab increased the number of adverse events, including hemorrhage, hypertension, infection and febrile neutropenia, but despite this, the ECOG status was not affected